Quest for the right Drug

|
עמוד הבית / קלבטן פורטה / מידע מעלון לרופא

קלבטן פורטה KALBETEN FORTE CAPLETS (BISMUTH SUBSALICYLATE)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

פומי : PER OS

צורת מינון:

קפליות : CAPLETS

Overdose : מינון יתר

4.9   Overdose

Bismuth
Bismuth intoxication may present as an acute encephalopathy with confusion, myoclonic movements, tremor, dysarthria and walking and standing disorders. Bismuth intoxication may also cause gastrointestinal disturbances, skin reactions, discolouration of mucous membranes, and renal dysfunction as a result of acute tubular necrosis. Treatment includes gastric lavage, purgation and hydration. Chelating agents may be effective in the early stages following ingestion and haemodialysis may be necessary.

Salicylate
Overdose of Kalbeten may also give symptoms of salicylate intoxification. Salicylate poisoning is usually associated with plasma concentrations >350 mg/L (2.5 mmol/L). Most adult deaths occur in patients whose concentrationsexceed 700 mg/L (95.1 mmol/L). Single doses less than 100 mg/kg are unlikely to cause serious poisoning.
If symptoms occur, use of Kalbeten should be discontinued. Management of overdose is the same as that for salicylate overdose:

Common features include vomiting, dehydration, tinnitus, vertigo, deafness, sweating, warm extremities with bounding pulses, increased respiratory rate andhyperventilation. Some degree of acid-base disturbance is present in most cases.

A mixed respiratory alkalosis and metabolic acidosis with normal or high arterial pH (normal or reduced hydrogen ion concentration) is usual in adults and children over the age of 4 years.
In children aged 4 years or less, a dominant metabolic acidosis with low arterial pH (raised hydrogen ion concentration) is common. Acidosis may increase salicylate transfer across the blood brain barrier.

Uncommon features include haematemesis, hyperpyrexia, hypoglycaemia, hypokalaemia, thrombocytopaenia, increased INR/PTR, intravascular coagulation, renal failure and non- cardiac pulmonary oedema.
Central nervous system features including confusion, disorientation, coma andconvulsions are less common in adults than in children.


Management
Give activated charcoal if an adult presents within one hour of ingestion of more than 250 mg/kg. The plasma salicylate concentration should be measured, although the severity of poisoning cannot be determined from this alone and the clinical and biochemical features must be taken into account. Elimination is increased by urinary alkalinisation, which is achieved by the administration of 1.26% sodium bicarbonate. The urine pH should be monitored. Correct metabolic acidosis with intravenous 8.4% sodium bicarbonate (first check serum potassium).
Forced diuresis should not be usedsince it does not enhance salicylate excretion and may cause pulmonary oedema.

Haemodialysis is the treatment of choice for severe poisoning and should be considered in patients with plasma salicylate concentrations >700 mg/L (5.1 mmol/L), or lower concentrations associated with severe clinical or metabolicfeatures. Patients under 10 years or over 70 have increased risk of salicylate toxicity and may require dialysis at an earlier stage.

שימוש לפי פנקס קופ''ח כללית 1994 Diarrhea
תאריך הכללה מקורי בסל 01/01/1995
הגבלות תרופה שאושרה לשימוש כללי בקופ'ח

בעל רישום

SAM-ON LTD

רישום

140 95 31841 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

21.05.24 - עלון לרופא 14.11.24 - עלון לרופא

עלון מידע לצרכן

13.05.15 - עלון לצרכן אנגלית 13.05.15 - עלון לצרכן עברית 13.05.15 - עלון לצרכן ערבית 21.05.24 - עלון לצרכן אנגלית 21.05.24 - עלון לצרכן עברית 21.05.24 - עלון לצרכן ערבית 14.11.24 - עלון לצרכן עברית 24.11.14 - החמרה לעלון 20.01.15 - החמרה לעלון

לתרופה במאגר משרד הבריאות

קלבטן פורטה

קישורים נוספים

RxList WebMD Drugs.com